Literature DB >> 9426040

Familial dilated cardiomyopathy: cardiac abnormalities are common in asymptomatic relatives and may represent early disease.

M K Baig1, J H Goldman, A L Caforio, A S Coonar, P J Keeling, W J McKenna.   

Abstract

OBJECTIVES: This study sought to determine whether early disease is identifiable in asymptomatic relatives of patients with dilated cardiomyopathy (DCM) by means of noninvasive cardiologic assessment.
BACKGROUND: DCM is diagnosed on the basis of advanced heart failure, where cardiac dilation and impaired contractility are recognized in the absence of a recognized etiology (World Health Organization criteria). However, initial clinical presentation may be with severe complications: thromboembolism, arrhythmia or sudden death. DCM has recently been recognized to be familial, with autosomal dominant inheritance in many cases. Familial disease is present in 9% to 20% of patients with DCM, and the ability to identify early disease in such people may improve patient management and aid in the understanding of pathogenesis.
METHOD: We prospectively assessed 408 asymptomatic relatives (mean [+/-SD] age 35 +/- 15 years, 193 men) of 110 consecutive patients with DCM by means of history and physical examination, two-dimensional echocardiography, 12-lead and signal-averaged electrocardiography and metabolic exercise testing. We hypothesized that signs of lesser cardiac dysfunction in such relatives might indicate early disease.
RESULTS: Twenty-nine percent of relatives had abnormal results on the echocardiogram. Twenty percent (n = 45) had left ventricular enlargement (LVE), defined as LV end-diastolic diameter (LVEDD) > or = 112% predicted; 6% (n = 13) had depressed fractional shortening (dFS), defined as FS < or = 25%; and 3% (n = 7) had frank DCM, defined as LV dilation, impaired contractile performance and LVEDD > or = 112% plus FS < or = 25%. Other abnormalities of cardiac function were identified in relatives with LVE or dFS: A greater number with LVE had an abnormal metabolic exercise test result than normal relatives (9% vs. 1%, p < 0.05). Relatives with LVE and abnormal maximal oxygen consumption (VO2max) (defined as VO2max < 80% predicted) had a lower absolute VO2max than normal relatives (30 +/- 8 vs. 43 +/- 9 ml/min per kg, p = 0.01). The QRS duration (at the 25-Hz filter) on the signal-averaged electrocardiogram was prolonged in relatives with LVE (103 +/- 13 ms) and dFS (102 +/- 12 ms) compared with that of normal relatives (97 +/- 12 ms, p < 0.05). Over a mean 39-month follow-up period, 12 relatives with LVE (27%) and none with dFS developed symptomatic DCM (p < 0.0001). One relative with LVE died suddenly, and another underwent heart transplantation.
CONCLUSIONS: Nearly one-third of asymptomatic relatives (29%) have echocardiographic abnormalities, and 27% of such relatives progress to development of overt DCM. Early identification of such people would permit appropriate intervention that might influence the serious complications and mortality of this disease.

Entities:  

Mesh:

Year:  1998        PMID: 9426040     DOI: 10.1016/s0735-1097(97)00433-6

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  66 in total

1.  Plasma concentrations of N-terminal atrial natriuretic peptide are raised in asymptomatic relatives of dilated cardiomyopathy patients with left ventricular enlargement.

Authors:  J Grzybowski; Z T Bilinska; J Janas; E Michalak; W Ruzyllo
Journal:  Heart       Date:  2002-08       Impact factor: 5.994

2.  Homozygosity mapping and exome sequencing reveal GATAD1 mutation in autosomal recessive dilated cardiomyopathy.

Authors:  Jeanne L Theis; Katharine M Sharpe; Martha E Matsumoto; High Seng Chai; Asha A Nair; Jason D Theis; Mariza de Andrade; Eric D Wieben; Virginia V Michels; Timothy M Olson
Journal:  Circ Cardiovasc Genet       Date:  2011-09-30

3.  Genetic variation in the alternative splicing regulator RBM20 is associated with dilated cardiomyopathy.

Authors:  Marwan M Refaat; Steven A Lubitz; Seiko Makino; Zahid Islam; J Michael Frangiskakis; Haider Mehdi; Rebecca Gutmann; Michael L Zhang; Heather L Bloom; Calum A MacRae; Samuel C Dudley; Alaa A Shalaby; Raul Weiss; Dennis M McNamara; Barry London; Patrick T Ellinor
Journal:  Heart Rhythm       Date:  2011-10-17       Impact factor: 6.343

Review 4.  Update 2011: clinical and genetic issues in familial dilated cardiomyopathy.

Authors:  Ray E Hershberger; Jill D Siegfried
Journal:  J Am Coll Cardiol       Date:  2011-04-19       Impact factor: 24.094

Review 5.  Genetics of inherited cardiomyopathy.

Authors:  Daniel Jacoby; William J McKenna
Journal:  Eur Heart J       Date:  2011-08-02       Impact factor: 29.983

Review 6.  The genetics of congestive heart failure.

Authors:  Calum A MacRae
Journal:  Heart Fail Clin       Date:  2010-04       Impact factor: 3.179

7.  Facts, fancies and follies of drug-induced QT/QTc interval shortening.

Authors:  Marek Malik
Journal:  Br J Pharmacol       Date:  2010-01       Impact factor: 8.739

8.  Cardiac magnetic resonance imaging of myocardial contrast uptake and blood flow in patients affected with idiopathic or familial dilated cardiomyopathy.

Authors:  Michael Jerosch-Herold; David C Sheridan; Jessica D Kushner; Deirdre Nauman; Donna Burgess; Diana Dutton; Rami Alharethi; Duanxiang Li; Ray E Hershberger
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-07-25       Impact factor: 4.733

9.  Features and outcomes in utero and after birth of fetuses with myocardial disease.

Authors:  Vlasta Fesslova; Maurizio Mongiovì; Salvatore Pipitone; Jelena Brankovic; Laura Villa
Journal:  Int J Pediatr       Date:  2010-10-03

10.  Propionic acidemia as a cause of adult-onset dilated cardiomyopathy.

Authors:  Moniek Riemersma; Mark R Hazebroek; Appolonia T J M Helderman-van den Enden; Gajja S Salomons; Sacha Ferdinandusse; Martijn C G J Brouwers; Liesbeth van der Ploeg; Stephane Heymans; Jan F C Glatz; Arthur van den Wijngaard; Ingrid P C Krapels; Jörgen Bierau; Han G Brunner
Journal:  Eur J Hum Genet       Date:  2017-08-30       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.